TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Lisa A Carey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.